8-K: Sangamo Therapeutics Reports Positive Phase 3 Results for Hemophilia A Gene Therapy

Sangamo Therapeutics announced positive topline results from Pfizer's Phase 3 AFFINE trial for their hemophilia A gene therapy, giroctocogene fitelparvovec, showing significant reductions in bleeding rates.

Summary

• Sangamo Therapeutics reported on Pfizer's announcement of positive topline results from the Phase 3 AFFINE trial for giroctocogene fitelparvovec, a gene therapy for adults with moderately severe to severe hemophilia A.
• The trial met its primary objective, demonstrating superiority in reducing the total annualized bleeding rate (ABR) compared to routine Factor VIII (FVIII) replacement prophylaxis.
• A single dose of giroctocogene fitelparvovec resulted in a statistically significant reduction in mean total ABR, from 4.73 pre-infusion to 1.24 post-infusion.
• Key secondary endpoints were also met, with 84% of participants maintaining FVIII activity >5% at 15 months post-infusion.
• The mean treated ABR showed a 98.3% reduction from 4.08 pre-infusion to 0.07 post-infusion.
• The gene therapy was generally well-tolerated, with transiently elevated FVIII levels observed in some participants, but without impacting efficacy or safety.
• Sangamo is eligible to receive up to $220 million in milestone payments and royalties of 14% 20% on product sales if the therapy is approved and commercialized.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 3 trial, with significant improvements in patient outcomes and a clear path towards potential commercialization. The financial implications for Sangamo are also positive, with potential milestone payments and royalties.

Positives

• The gene therapy demonstrated a statistically significant reduction in bleeding rates compared to standard treatment.
• The majority of participants maintained clinically relevant FVIII activity levels after a single infusion.
• The treatment was generally well-tolerated with manageable adverse events.
• The results suggest a potential one-time treatment option for hemophilia A, reducing the burden of frequent infusions.
• The positive results validate Sangamo's genomic technologies and bring them closer to having their first commercially available medicine.

Negatives

• Serious adverse events were reported in 20% of patients, with 13.3% assessed as related to treatment.
• Transiently elevated FVIII levels were observed in 49.3% of participants, although without impacting efficacy or safety.

Risks

• The potential for Pfizer to breach or terminate its collaboration agreement with Sangamo exists.
• Sangamo may not realize the expected benefits from the Pfizer collaboration.
• There is no guarantee that Sangamo will earn any milestone or royalty payments under the Pfizer agreement.
• Regulatory approvals for the product candidate are not guaranteed.
• The commercialization of the product is subject to market conditions and competition.

Future Outlook

Pfizer will discuss the Phase 3 data with regulatory authorities in the coming months, and additional data will be presented at upcoming medical meetings. Sangamo anticipates the potential for giroctocogene fitelparvovec to become their first commercially available medicine.

Management Comments

• Professor Andrew Leavitt M.D. stated he is excited by the strength of the positive results from the AFFINE trial that show giroctocogene fitelparvovec was generally well tolerated, and demonstrate the transformative potential of this gene therapy candidate.
• Nathalie Dubois-Stringfellow, Ph.D, Chief Development Officer at Sangamo, said they are thrilled with the positive topline results and that they further validate the power of their genomic technologies.

Industry Context

The announcement is significant as it represents a major step forward in the development of gene therapies for hemophilia A, a market with a high unmet need. The success of this trial could position Sangamo and Pfizer as leaders in this space, especially given Pfizer's recent approval of a hemophilia B gene therapy.

Comparison to Industry Standards

• The results of the AFFINE trial are very promising when compared to traditional Factor VIII replacement therapy, which requires frequent infusions.
• The 98.3% reduction in mean treated ABR is a significant improvement over existing treatments.
• Pfizer's recent approval of BEQVEZ (fidanocogene elaparvovec) for hemophilia B sets a precedent for the potential regulatory pathway for giroctocogene fitelparvovec.
• Other companies such as BioMarin and uniQure are also developing gene therapies for hemophilia, making this a competitive space.

Stakeholder Impact

• Shareholders of Sangamo are likely to react positively to the news of successful trial results.
• Patients with hemophilia A stand to benefit from a potential one-time treatment option.
• Employees of Sangamo may experience increased job security and opportunities.
• Pfizer's stakeholders will also benefit from the potential commercial success of the gene therapy.

Next Steps

• Pfizer will discuss the data with regulatory authorities.
• Additional data from the AFFINE trial will be presented at upcoming medical meetings.
• Clinical trial participants will be evaluated in AFFINE over the course of five years, and up to a total of 15 years as part of a long-term follow-up trial.

Key Dates

Keywords

Hemophilia A, Gene Therapy, Giroctocogene Fitelparvovec, Sangamo Therapeutics, Pfizer, AFFINE Trial, Annualized Bleeding Rate, Factor VIII, Clinical Trial, Genomic Medicine